Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD5335 + Carboplatin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD5335 | AZD 5335|AZD-5335|Torvutatug Samrotecan | FOLR1-targeted Therapy 24 | AZD5335 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) linked to a topoisomerase 1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (8_Supplement): LB025). | |
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05797168 | Phase Ib/II | AZD5335 + Pembrolizumab AZD5335 + Bevacizumab + Carboplatin AZD5335 + Saruparib AZD5335 + Bevacizumab AZD5335 AZD5335 + AZD9574 + Pembrolizumab AZD5335 + AZD9574 AZD5335 + AZD9574 + Bevacizumab AZD5335 + Carboplatin | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors (FONTANA) | Recruiting | USA | TUR | ISR | GBR | ESP | DEU | CAN | AUS | 4 |